

# Hideyuki Hyogo

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6430918/hideyuki-hyogo-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

80  
papers

2,753  
citations

25  
h-index

51  
g-index

82  
ext. papers

3,469  
ext. citations

4.7  
avg, IF

4.35  
L-index

#	Paper	IF	Citations
80	Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-Based Cohort Study.. <i>Clinical Gastroenterology and Hepatology</i> , <b>2022</b> ,	6.9	2
79	Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	1
78	Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2021</b> , 36, 2275-2284	4.84	6
77	Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD. <i>Hepatology Communications</i> , <b>2021</b> ,	6	9
76	Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma. <i>Oncology</i> , <b>2021</b> , 99, 507-517	3.6	5
75	Prediction of Nonalcoholic Fatty Liver Disease Using Noninvasive and Non-Imaging Procedures in Japanese Health Checkup Examinees. <i>Diagnostics</i> , <b>2021</b> , 11,	3.8	3
74	Clinical Outcomes of 2nd- and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma. <i>Oncology</i> , <b>2021</b> , 99, 491-498	3.6	
73	The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995-2040. <i>Hepatology International</i> , <b>2021</b> , 15, 366-379	8.8	14
72	FIB-4 First in the Diagnostic Algorithm of Metabolic-Dysfunction-Associated Fatty Liver Disease in the Era of the Global Metabodemic. <i>Life</i> , <b>2021</b> , 11,	3	6
71	Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study. <i>BMC Gastroenterology</i> , <b>2021</b> , 21, 306	3	5
70	Predictive value of cytokeratin-18 fragment levels for diagnosing steatohepatitis in patients with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2021</b> , 33, 1451-1458	2.2	0
69	Self-expandable Metallic Stent for Obstructive Colorectal Cancer in Our Hospital: Evaluation of Short-term Benefit. <i>Journal of the Japanese Association of Rural Medicine</i> , <b>2021</b> , 69, 506-509	0	
68	Metabolomic/lipidomic-based analysis of plasma to diagnose hepatocellular ballooning in patients with non-alcoholic fatty liver disease: A multicenter study. <i>Hepatology Research</i> , <b>2020</b> , 50, 955-965	5.1	6
67	Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	22
66	Serum miR-379 expression is related to the development and progression of hypercholesterolemia in non-alcoholic fatty liver disease. <i>PLoS ONE</i> , <b>2020</b> , 15, e0219412	3.7	10
65	Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib. <i>Oncology</i> , <b>2020</b> , 98, 787-797	3.6	13
64	ALT Levels for Asians With Metabolic Diseases: A Meta-analysis of 86 Studies With Individual Patient Data Validation. <i>Hepatology Communications</i> , <b>2020</b> , 4, 1624-1636	6	13

63	Serum miR-379 expression is related to the development and progression of hypercholesterolemia in non-alcoholic fatty liver disease <b>2020</b> , 15, e0219412		
62	Serum miR-379 expression is related to the development and progression of hypercholesterolemia in non-alcoholic fatty liver disease <b>2020</b> , 15, e0219412		
61	Serum miR-379 expression is related to the development and progression of hypercholesterolemia in non-alcoholic fatty liver disease <b>2020</b> , 15, e0219412		
60	Serum miR-379 expression is related to the development and progression of hypercholesterolemia in non-alcoholic fatty liver disease <b>2020</b> , 15, e0219412		
59	Clinical features of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without advanced fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2019</b> , 34, 1626-1632	4	12
58	Infection phase is a predictor of pruritus in patients with hepatitis B virus infection. <i>Biomedical Reports</i> , <b>2019</b> , 11, 63-69	1.8	0
57	HOMA-IR: An independent predictor of advanced liver fibrosis in nondiabetic non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2019</b> , 34, 1390-1395	4	38
56	Epidemiological survey of hemoglobin A1c and liver fibrosis in a general population with non-alcoholic fatty liver disease. <i>Hepatology Research</i> , <b>2019</b> , 49, 296-303	5.1	16
55	Evaluation of postprandial hypoglycemia in patients with nonalcoholic fatty liver disease by oral glucose tolerance testing and continuous glucose monitoring. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2018</b> , 30, 797-805	2.2	2
54	Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2018</b> , 33, 1700-1706	4	21
53	Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis. <i>Oncology</i> , <b>2018</b> , 94, 215-222	3.6	25
52	Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts the development of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. <i>Hepatology Research</i> , <b>2018</b> , 48, 521-528	5.1	12
51	Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , <b>2018</b> , 53, 269-280	6.9	44
50	Prevalence of pruritus in patients with chronic liver disease: A multicenter study. <i>Hepatology Research</i> , <b>2018</b> , 48, E252-E262	5.1	27
49	Palmitate-induced lipotoxicity is crucial for the pathogenesis of nonalcoholic fatty liver disease in cooperation with gut-derived endotoxin. <i>Scientific Reports</i> , <b>2018</b> , 8, 11365	4.9	46
48	Evaluation of glycemic variability in chronic liver disease patients with type 2 diabetes mellitus using continuous glucose monitoring. <i>PLoS ONE</i> , <b>2018</b> , 13, e0195028	3.7	10
47	A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD. <i>Scientific Reports</i> , <b>2018</b> , 8, 10434	4.9	25
46	The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study. <i>Journal of Gastroenterology</i> , <b>2018</b> , 53, 1216-1224	6.9	37

45	A case of dual oral therapy for elderly patients with acute hepatitis C. <i>Acta Hepatologica Japonica</i> , <b>2017</b> , 58, 197-201	0.3	
44	Significance of non-alcoholic fatty liver disease in Crohn's disease: A retrospective cohort study. <i>Hepatology Research</i> , <b>2017</b> , 47, 872-881	5.1	10
43	The risk of transient postprandial oxyhypoglycemia in nonalcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , <b>2017</b> , 52, 253-262	6.9	3
42	Choline Deficiency Causes Colonic Type II Natural Killer T (NKT) Cell Loss and Alleviates Murine Colitis under Type I NKT Cell Deficiency. <i>PLoS ONE</i> , <b>2017</b> , 12, e0169681	3.7	12
41	Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease. <i>Scientific Reports</i> , <b>2016</b> , 6, 35282	4.9	55
40	Interleukin-34 as a fibroblast-derived marker of liver fibrosis in patients with non-alcoholic fatty liver disease. <i>Scientific Reports</i> , <b>2016</b> , 6, 28814	4.9	32
39	Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease: multicenter survey. <i>Journal of Gastroenterology</i> , <b>2016</b> , 51, 586-96	6.9	33
38	Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. <i>Gastroenterology</i> , <b>2016</b> , 150, 626-637.e7	13.3	438
37	The impact of PNPLA3 and JAZF1 on hepatocellular carcinoma in non-viral hepatitis patients with type 2 diabetes mellitus. <i>Journal of Gastroenterology</i> , <b>2016</b> , 51, 370-9	6.9	33
36	Characteristics of non-obese non-alcoholic fatty liver disease: Effect of genetic and environmental factors. <i>Hepatology Research</i> , <b>2016</b> , 46, 1011-8	5.1	39
35	Influence of the rs738409 polymorphism in patatin-like phospholipase 3 on the treatment efficacy of non-alcoholic fatty liver disease with type 2 diabetes mellitus. <i>Hepatology Research</i> , <b>2016</b> , 46, E146-53	5.1	16
34	Morbidly obese patient with non-alcoholic steatohepatitis-related cirrhosis who died from sepsis caused by dental infection of <i>Porphyromonas gingivalis</i> : A case report. <i>Hepatology Research</i> , <b>2016</b> , 46, E210-5	5.1	7
33	Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization. <i>Anticancer Research</i> , <b>2016</b> , 36, 3523-9	2.3	20
32	Efficacy of radiofrequency ablation for initial recurrent hepatocellular carcinoma after curative treatment: Comparison with primary cases. <i>European Journal of Radiology</i> , <b>2015</b> , 84, 1540-1545	4.7	14
31	Biphasic effect of alcohol intake on the development of fatty liver disease. <i>Journal of Gastroenterology</i> , <b>2015</b> , 50, 1114-23	6.9	21
30	Usefulness of combining gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for diagnosing the macroscopic classification of small hepatocellular carcinoma. <i>European Radiology</i> , <b>2015</b> , 25, 3272-81	8	12
29	The Association between Glyceraldehyde-Derived Advanced Glycation End-Products and Colorectal Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2015</b> , 24, 1855-63	4	25
28	Role of 3-D conformal radiotherapy for major portal vein tumor thrombosis combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. <i>Hepatology Research</i> , <b>2015</b> , 45, 607-17	5.1	32

27	Disseminated carcinomatosis of the bone marrow originating from hepatocellular carcinoma. A case report. <i>Hepatology Research</i> , <b>2015</b> , 45, 705-10	5.1	4
26	Sustained virological response to antiviral therapy improves survival rate in patients with recurrent hepatitis C virus infection after liver transplantation. <i>Hepatology Research</i> , <b>2015</b> , 45, 1047-54	5.1	14
25	Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis. <i>Hepatology Research</i> , <b>2015</b> , 45, 656-62	5.1	36
24	Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma. <i>Journal of Digestive Diseases</i> , <b>2015</b> , 16, 505-12	3.3	30
23	A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycomarkers. <i>Hepatology</i> , <b>2015</b> , 62, 1433-43	11.2	48
22	Elevation of Serum Levels of Advanced Glycation End Products in Patients With Non-B or Non-C Hepatocellular Carcinoma. <i>Journal of Clinical Laboratory Analysis</i> , <b>2015</b> , 29, 480-4	3	22
21	Osteodystrophy in Cholestatic Liver Diseases Is Attenuated by Anti-EGlutamyl Transpeptidase Antibody. <i>PLoS ONE</i> , <b>2015</b> , 10, e0139620	3.7	6
20	Serum asymmetric dimethylarginine levels are independently associated with procollagen III N-terminal peptide in nonalcoholic fatty liver disease patients. <i>Clinical and Experimental Medicine</i> , <b>2014</b> , 14, 45-51	4.9	1
19	Targeted next-generation sequencing and fine linkage disequilibrium mapping reveals association of PNPLA3 and PARVB with the severity of nonalcoholic fatty liver disease. <i>Journal of Human Genetics</i> , <b>2014</b> , 59, 241-6	4.3	14
18	Uric acid levels decrease with fibrosis progression in patients with nonalcoholic fatty liver disease. <i>Clinical Biochemistry</i> , <b>2014</b> , 47, 1138-9	3.5	7
17	LDL-migration index (LDL-MI), an indicator of small dense low-density lipoprotein (sdLDL), is higher in non-alcoholic steatohepatitis than in non-alcoholic fatty liver: a multicenter cross-sectional study. <i>PLoS ONE</i> , <b>2014</b> , 9, e115403	3.7	25
16	Efficacy of probucol for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label pilot study. <i>Hepatology Research</i> , <b>2014</b> , 44, 429-35	5.1	8
15	Upper limit of normal serum alanine aminotransferase levels in Japanese subjects. <i>Hepatology Research</i> , <b>2014</b> , 44, 1196-207	5.1	13
14	Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. <i>Journal of Gastroenterology</i> , <b>2014</b> , 49, 1477-84	6.9	87
13	sRAGE is associated with low waist circumference and Hb levels in NAFLD. <i>Open Medicine (Poland)</i> , <b>2013</b> , 8, 830-834	2.2	
12	Serum levels of pigment epithelium-derived factor (PEDF) are independently associated with procollagen III N-terminal peptide levels in patients with nonalcoholic fatty liver disease. <i>Clinical Biochemistry</i> , <b>2012</b> , 45, 1554-7	3.5	3
11	Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor- $\alpha$ -lowering property. <i>Digestive and Liver Disease</i> , <b>2012</b> , 44, 492-6	3.3	45
10	Increased insulinogenic index is an independent determinant of nonalcoholic fatty liver disease activity score in patients with normal glucose tolerance. <i>Digestive and Liver Disease</i> , <b>2012</b> , 44, 935-9	3.3	3

9	Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. <i>BMC Gastroenterology</i> , <b>2012</b> , 12, 2	3	210
8	Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. <i>Journal of Gastroenterology</i> , <b>2012</b> , 47, 586-95	6.9	314
7	A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , <b>2011</b> , 46, 257-68	6.9	158
6	Platelet count for predicting fibrosis in nonalcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , <b>2011</b> , 46, 1300-6	6.9	77
5	Reply to the letter by I. Tasci regarding the clinical usefulness of AGEs as a biomarker for the attenuation of NASH. <i>Journal of Gastroenterology</i> , <b>2010</b> , 45, 781-781	6.9	
4	Reply to the letter by Y. Yilmaz regarding the AGEs/RAGE axis and nonalcoholic steatohepatitis. <i>Journal of Gastroenterology</i> , <b>2010</b> , 45, 784-784	6.9	
3	Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. <i>Metabolism: Clinical and Experimental</i> , <b>2008</b> , 57, 1711-8	12.7	156
2	Advanced glycation end products (AGEs) and their involvement in liver disease. <i>Current Pharmaceutical Design</i> , <b>2008</b> , 14, 969-72	3.3	102
1	Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2007</b> , 22, 1112-9	4	136